Dabrafenib Production Cost Reports

The report provides a detailed analysis essential for establishing a Dabrafenib production plant. It encompasses all critical aspects necessary for Dabrafenib production, including the cost of Dabrafenib production, Dabrafenib plant cost, Dabrafenib production costs, and the overall Dabrafenib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Dabrafenib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Dabrafenib is a pharmaceutical compound used primarily in the treatment of certain types of cancer, especially melanoma and non-small cell lung cancer. It is a targeted therapy that works by inhibiting a specific protein called BRAF, which is involved in the growth and spread of cancer cells. It works by inhibiting a mutated form of the BRAF protein, which is commonly found in several cancers, including skin, lung, and colorectal cancers.

It is also prescribed to treat melanomas that have a BRAF V600 mutation, which helps to slow the progression of the disease. It is often used in combination with other drugs, such as trametinib, to increase its effectiveness in targeting cancer cells. It is also studied for its potential applications in combination therapies, which help to improve the survival rates of patients with advanced cancer by slowing down the growth of tumours.

The market for Dabrafenib is driven by its application in the treatment of cancers, particularly melanoma and non-small cell lung cancer (NSCLC), which fuels its demand in the oncology and pharmaceutical industries. Its application as an anticancer drug in the treatment of melanoma, non-small cell lung cancer, and other cancers with BRAF mutations also boosts its demand in the medical and pharmaceutical industries.

Its demand as a targeted therapy in precision medicine for its effectiveness in targeting specific cancer mutations also fuels its market expansion. Its usage in combination therapies with other cancer treatments, such as trametinib, further promotes its demand in the medical sector. Several factors, including the cost and availability of raw materials, regulatory compliance with stringent health standards, and environmental guidelines, significantly impact industrial Dabrafenib procurement. Moreover, technological advancements in drug production, supplier reliability, sustainability practices, and efficient logistics play a significant role in shaping global Dabrafenib procurement strategies.

Raw Material for Dabrafenib Production

According to the Dabrafenib production plant project report, the major raw materials for Dabrafenib production include Fluoroaniline, 2,5-Difluorobenzenesulfonyl Chloride, 2,2-Dimethylpropanethioamide, and Methanesulfonic Acid.

Production Process of Dabrafenib

The extensive Dabrafenib production cost report consists of the following industrial production process:

1. Production from Fluoroaniline: The production process of Dabrafenib mesylate begins with the conversion of fluoroaniline to sulfonamide by reacting it with 2,5-difluorobenzenesulfonyl chloride in the presence of pyridine. Then, 2-chloro-4-methylpyrimidine is deprotonated with lithium bis(trimethylsilyl)amide and reacted with an ester to form chloropyrimidine. Further, this chloropyrimidine undergoes bromination followed by thiazole formation using 2,2-dimethylpropanethioamide, giving the penultimate intermediate. The chloropyrimidine undergoes an SNAr reaction with ammonium hydroxide to produce aminopyrimidine, which is then treated with methanesulfonic acid to obtain dabrafenib mesylate as the final product.

Dabrafenib is a thiazole derivative that appears as a white to off-white solid powder. The molecular formula of the compound is C23H20F3N5O2S2, and its molecular mass is 519.56 g/mol. The compound has a melting point of 214–216 degree Celsius and a boiling point of approximately 653.7 degree Celsius. The density of the compound is 1.443 g/cm³, and it is generally insoluble in water but soluble in dimethyl sulfoxide (DMSO) and dimethylformamide (DMF). Dabrafenib is an FDA-approved drug and is marketed under the brand name Tafinlar. Extended use of this substance may cause side effects such as papilloma, hyperkeratosis, hair loss, skin rash, joint pain, fever, nausea, and fatigue. It is recommended to store the compound in dry, dark conditions at 0–4 degree Celsius for short-term storage or at -20degree Celsius for long-term stability.